ps3 philippines

NoneA late power-play goal by Kaapo Kakko lifted the New York Rangers to their first win in six games, as they beat the visiting Montreal Canadiens 4-3 in a matinee on Saturday. With the score tied 3-3, Canadiens forward Kirby Dach took an ill-advised high-sticking double-minor, cutting Mika Zibanejad deep in the Rangers zone. With time winding down, a falling/tripped up Joel Armia and Jake Evans couldn’t get the puck out, enabling the Rangers to capitalize. Rangers forward Will Cuylle , who facilitated Armia’s fall to the ice, eventually ended up with the puck on his stick. He then delivered a nifty backhand feed to Kakko, who slid it past Samuel Montembeault for the 4-3 game-winning goal at 19:36. It was something of a redemption story for Cuylle. He had been unable to get the puck out of his own zone on Nick Suzuki’s game-tying goal 5:30 earlier. Defenseman Lane Hutson kept it in, giving and going with Cole Caufield , who found Suzuki for the tip-in past Rangers goalie Jonathan Quick. Caufield had scored 10 minutes earlier to pull the Canadiens within one, after they had fallen behind 3-1, late goals in each frame and an underwhelming penalty kill that allowed three overall, ultimately doing the now 8-12-3 Habs in. With the score tied 1-1, Vincent Trocheck deflected in an Alexis Lafreniere shot with just four seconds left in the first. Zibanejad also scored with less than three minutes to go in the second, before the Canadiens attempted to earn their first point(s) of the season after trailing after two periods in a game. They are no 0-10-0 under those circumstances, with one such game, a 7-2 defeat, coming Oct. 22 against the Rangers . Considering the magnitude of that loss, there were positives the Canadiens could take away from this defeat. They kept things close, nearly completed an impressive comeback and actually held a late lead in shots on goal against an initial Stanley Cup contender, despite being near the bottom of the league in terms of expected goals percentage for (45.15%, ranked 29th, per MoneyPuck.com ). As a result of the Dach penalty and the Rangers ending up with a late power play though, shots ended up at 28 apiece. For their part, the Rangers got back into the win column . They had last won Nov. 19, 4-3 against the Vancouver Canucks . Both Chris Kreider and Filip Chytil returned to the lineup after extended absences. Canadiens defenseman Mike Matheson also returned after missing two games. His delay-of-game penalty led to a two-man advantage for the Rangers, leading to Artemi Panarin’s game-opening goal. Matheson got that one back later in the frame, setting the stage for all the late-goal and uncompleted-comeback theatrics that ensued. The 13-9-1 Rangers next play on Monday, Dec. 2, hosting the New Jersey Devils. The Canadiens visit the Boston Bruins tomorrow in another matinee before returning home to face the New York Islanders on Tuesday, Dec. 3. This article first appeared on The Hockey Writers and was syndicated with permission.ps3 philippines 。

Religare's Rashmi Saluja 7th highest-paid CEO at over ₹68 crore in FY24None

Dr. Rob’s new AI model promises to cut aircraft design time from months to daysMARLBOROUGH, Mass.--(BUSINESS WIRE)--Dec 17, 2024-- CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced the first series of patients treated with the investigational OptiShotTM Pulsed Field Ablation (PFA) System for the treatment of paroxysmal atrial fibrillation as part of the VISION AF clinical trial. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241217582090/en/ Image: [A] Endoscopic view of LSPV, [B]&[D] OptiShot Balloon, [C]&[E] Post PFA map (Photo: Business Wire) Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital and Prof. Petr Neužil, Chief of Cardiology at Na Homolce Hospital, performed the first cases at Na Homolce Hospital, Prague, Czech Republic. The first-in-human trial will treat up to 50 patients in the coming months with 12-month follow-up planned, including critical remapping procedures to validate the efficacy of this novel technology. “The OptiShot balloon catheter is unique among the advanced generation of PFA catheters, with its ability to deliver circumferential lesions to the pulmonary veins with endoscopic visual confirmation of electrode-tissue contact,” said Dr. Reddy. “Direct contact confirmation made me more confident that our acute treatment strategy with this system may provide good long-term outcomes.” Professor Petr Neužil said, “The ultra-compliant balloon allows for adaptation to all anatomies with unparallelled tissue contact and precise pulsed electric field energy delivery. This design is focused on raising the bar for patient outcomes and we look forward to continuing the study.” “CardioFocus has combined our expertise in pulsed field waveforms with our clinically proven compliant balloon system to create OptiShot, a next generation PFA system for the treatment of atrial fibrillation,” said CardioFocus CEO Steve Ogilvie. “We are one step closer toward providing a true single shot pulmonary vein isolation tool, designed for safe and effective patient treatment. We are thankful to our electrophysiologist partners as well as the CardioFocus team and advisors for making this remarkable achievement happen.” CardioFocus is taking a portfolio approach to PFA. In addition to OptiShot, CardioFocus will continue clinical trials evaluating the investigational QuickShotTM PFA System, a large area focal ablation catheter that integrates with various navigation technologies. In the EU CardioFocus has treated over 6000 patients with the Centauri PFA System, which uses a proprietary monopolar waveform with marketed contact-force sensing focal ablation catheters and mapping systems. The OptiShot PFA Balloon System is investigational and not approved for commercial use. About CardioFocus, Inc. Headquartered in Marlborough, MA, CardioFocus is a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation, the most common heart arrhythmia. For more information, visit CardioFocus.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20241217582090/en/ CONTACT: Media Relations [Pete Bell.pbell@cardiofocus.com ] KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH HOSPITALS CLINICAL TRIALS CARDIOLOGY BIOTECHNOLOGY SOURCE: CardioFocus, Inc. Copyright Business Wire 2024. PUB: 12/17/2024 03:09 PM/DISC: 12/17/2024 03:10 PM http://www.businesswire.com/news/home/20241217582090/en